ATP citrate lyase as a prognostic biomarker and target for immune therapy in children with sepsis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000036585

Enrollment

Unknown

Registered

2020-08-24

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

sepsis without immunosuppression:none

survivors:none

non-survivors:none

sepsis-associated immunosuppression:none

Eligibility

Sex/Gender

All

Age

No minimum to 14 Years

Inclusion criteria

Inclusion criteria: 1. Children diagnosed with sepsis according to the International Pediatric Sepsis Consensus Conference definition in 2005; 2. Patients who were hospitalized in PICU for more than 3 days; 3. Aged 29 days to 14 years; 4. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who had inherited metabolic diseases; 2. Patients who had acute leukemia and malignant tumors; 3. Patients who used glucocorticoid drugs and immunosuppressive drugs within three months.

Design outcomes

Primary

Measure	Time frame
hospital mortality;ATP Citrate Lyase;PRISM III score;index for immune function;indicators for organ function;	—

Countries

China

Contacts

Public ContactWang Chunxia

karencx0465@163.com+86 18017329197

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026